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Typhoid fever and paratyphoid fever: 
Systematic review to estimate global 
morbidity and mortality for 2010
Background Typhoid and paratyphoid fever remain important 
causes of morbidity worldwide. Accurate disease burden estimates 
are needed to guide policy decisions and prevention and control 
strategies.
Methods We conducted a systematic literature review of the PubMed 
and Scopus databases using pre-defined criteria to identify popula-
tion-based studies with typhoid fever incidence data published be-
tween 1980 and 2009. We also abstracted data from annual reports 
of notifiable diseases in countries with advanced surveillance sys-
tems. Typhoid and paratyphoid fever input data were grouped into 
regions and regional incidence and mortality rates were estimated. 
Incidence data were extrapolated across regions for those lacking 
data. Age-specific incidence rates were derived for regions where 
age-specific data were available. Crude and adjusted estimates of the 
global typhoid fever burden were calculated.
Results Twenty-five studies were identified, all of which contained 
incidence data on typhoid fever and 12 on paratyphoid fever. Five 
advanced surveillance systems contributed data on typhoid fever; 2 
on paratyphoid fever. Regional typhoid fever incidence rates ranged 
from <0.1/100 000 in Central and Eastern Europe and Central Asia 
to 724.6/100 000 in Sub-Saharan Africa. Regional paratyphoid in-
cidence rates ranged from 0.8/100 000 in North Africa/Middle East 
to 77.4/100 000 in Sub-Saharan Africa and South Asia. The estimat-
ed total number of typhoid fever episodes in 2010 was 13.5 million 
(interquartile range 9.1–17.8 million). The adjusted estimate ac-
counting for the low sensitivity of blood cultures for isolation of the 
bacteria was 26.9 million (interquartile range 18.3–35.7 million) 
episodes. These findings are comparable to the most recent analysis 
of global typhoid fever morbidity, which reported crude and adjust-
ed estimates of 10.8 million and 21.7 million typhoid fever episodes 
globally in 2000.
Conclusion Typhoid fever remains a significant health burden, es-
pecially in low- and middle-income countries. Despite the availabil-
ity of more recent data on both enteric fevers, additional research is 
needed in many regions, particularly Africa, Latin America and oth-
er developing countries.
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Typhoid and paratyphoid fever remain important public 
health problems globally and major causes of morbidity in 
the developing world [1]. Typhoid and paratyphoid fever 
are acute and often life-threatening febrile illnesses caused 
by systemic infection with the bacterium Salmonella enteri-
ca serotype typhi and paratyphi, respectively. Classical 
symptoms include gradual onset of sustained fever, chills, 
hepatosplenomegaly and abdominal pain. In some cases, 
patients experience rash, nausea, anorexia, diarrhea or con-
stipation, headache, relative bradycardia and reduced level 
of consciousness [2]. While both diseases share clinical fea-
tures, paratyphoid fever tends to have a more benign course 
of illness. Without effective treatment, typhoid fever has a 
case-fatality rate of 10–30%. This number is reduced to 
1–4% in those receiving appropriate therapy [1].
The most recent global burden of disease estimates for ty-
phoid and paratyphoid fever reported that in 2000, there 
were 22 million new cases of typhoid fever, 210 000 ty-
phoid fever-related deaths, and 5.4 million cases of para-
typhoid fever [1]. This study offered improved estimates 
from past updates and analyses [1,3-6].
A revised estimate of the global burden of typhoid and 
paratyphoid fever is critically needed for developing im-
proved strategies for disease prevention and control. The 
global epidemiology of these diseases has changed with 
global population growth and provision of clean water and 
sanitation systems. Advances in surveillance, improved un-
derstanding of the age distribution of the disease, and more 
recent studies allow for updated estimates of the global bur-
den of typhoid and paratyphoid fever.
METHODS
Systematic review and data extraction
We conducted literature searches in PubMed and Scopus 
databases using combinations of the following search 
terms: typhoid; Salmonella typhi; Salmonella paratyphi; inci-
dence; prevalence; mortality; disease burden; surveillance; dis-
tribution. The initial literature search was conducted in Jan-
uary 2009 and was updated on December 31, 2009. We 
screened study titles and abstracts focused on typhoid and/
or enteric fever according to a priori inclusion and exclu-
sion criteria. For papers not excluded based on title and 
abstract, full text articles were obtained and reevaluated for 
inclusion/exclusion criteria. We sought to include all stud-
ies published from 1980–2009 collecting prospective, pop-
ulation-based typhoid fever incidence data with blood cul-
ture confirmation of diagnosis from both active and passive 
surveillance studies. Intervention studies were included, 
but estimates were based on non-intervention groups only. 
Studies published in English, Spanish, Italian, Portuguese, 
or French were included. We excluded studies that did not 
diagnose typhoid fever by blood culture or that used stool 
culture for diagnosis. We also excluded case reports, mi-
crobiological reports, studies of carriers, and studies whose 
results did not allow for separation of S. typhi and S. para-
typhi cases. Studies of hospitalized patients were excluded 
unless differentiation between inpatients and outpatients 
was clear; however, studies that screened for typhoid fever 
among individuals presenting with febrile illness at clinics/
hospitals were considered separately from studies of hos-
pitalized patients. We only included systematic review pa-
pers and excluded all commentaries. We abstracted data 
from the annual reports of notifiable diseases in countries 
with advanced surveillance systems.
Analytic methods
Because of the scarcity of information, input data for ty-
phoid and paratyphoid fever were grouped into the 7 Super 
Regions as defined by the Global Burden of Disease Project 
(Super Region 1: Australasia, Southern Latin America, High 
Income North America, High Income Asia Pacific; Super 
Region 2: Western Europe, Eastern Europe, Central Europe, 
Central Asia; Super Region 3: Southern Sub-Saharan Africa, 
Central Sub-Saharan Africa, West Sub-Saharan Africa, East 
Sub-Saharan Africa; Super Region 4: Northern Africa/Mid-
dle East; Super Region 5: South Asia; Super Region 6: East 
Asia, South East Asia; Super Region 7: Caribbean, Andean 
Latin America, Central Latin America, Tropical Latin Amer-
ica, Oceania) [7]. We estimated the incidence using data 
from all eligible studies conducted within the correspond-
ing Super Region and regional groupings. For any Super 
Region lacking data on paratyphoid fever, we extrapolated 
an incidence estimate from the Super Region with the clos-
est typhoid fever incidence estimate.
Typhoid fever incidence rates were grouped with respect to 
age (ie, children <5 years and persons ≥5 years) for regions 
where age-specific data were available. The median propor-
tion of typhoid fever cases observed among children <5 
years of age was calculated and this figure was used to de-
rive the estimated proportion of cases among those 5 years 
of age and older. We then calculated age-specific incidence 
rates and the annual number of typhoid fever episodes 
within each age strata using the median proportion of ty-
phoid fever cases among each age group and the estimated 
number of overall typhoid fever episodes across all ages.
To estimate the number of typhoid fever episodes in each 
Super Region for 2010, we applied the median incidence 
for each Super Region to the corresponding population es-
timates. Uncertainty bounds were calculated using inter-
quartile ranges. The total episodes were summed across 
Super Regions to provide the crude global typhoid fever 
burden and estimates of uncertainty.V
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An adjusted estimate of global typhoid fever burden was 
also calculated to account for the low sensitivity of the 
blood culture to isolate S. typhi or S. paratyphi. Similar to 
previous estimates by Crump et al., an adjustment factor 
of 2 was chosen based on a conservative estimate of 50% 
sensitivity [1]. This figure was the lowest reported sensitiv-
ity among 3 studies evaluating this culture method for ty-
phoid fever diagnosis [8-10].
We estimated case-fatality rates for typhoid and paraty-
phoid fever from the published literature and the surveil-
lance system data and applied to incidence rate estimates 
to calculate mortality rates.
RESULTS
The systematic review yielded 24 studies that examined 
typhoid fever incidence and employed blood culture as the 
criteria for diagnosis (Figure 1) [11-34]. Five advanced 
surveillance systems reporting blood-culture confirmed ty-
phoid fever cases were also identified [35-39]. In addition, 
after the manuscript was accepted, we became aware of one 
recently published study that met systematic review inclu-
sion criteria, so the analysis was updated to include this 
data [40]. In total, typhoid fever incidence data was ab-
stracted from 47 countries across 14 (67%) of the 21 re-
gions (Table 1). Population-based and prospective vaccine 
studies contributed data for 13 countries across 8 regions. 
The remaining incidence data was collected by typhoid fe-
ver surveillance systems in the 6 developed regions, each 
of which includes 1 or more countries with national-level 
surveillance. The developed regions include: High Income 
Asia Pacific, High Income North America, Central Europe, 
Eastern Europe, Western Europe, and Australia/New Zea-
land. Overall, our analysis includes national-level incidence 
data from 34 countries across these regions. Paratyphoid 
fever incidence data was available for 9 countries represent-
ing 7 (33%) of the 21 regions (Table 2). Only 2 regions 
included national-level surveillance systems reporting 
paratyphoid fever incidence (High Income Asia Pacific and 
Australia/New Zealand). Population-based studies provid-
ed paratyphoid fever data for 7 countries in 5 of the regions 
(Southern Latin America, North Africa/Middle East, South 
Asia, South East Asia, and East Asia). The median year of 
data collection for included studies is 2004.
Input data for typhoid and paratyphoid fever were grouped 
into 7 Super Regions and median incidence rates and in-
terquartile ranges are presented in Tables 1 and 2, respec-
tively. Paratyphoid fever incidence estimates were extrapo-
lated between Super Regions on the basis of typhoid fever 
burden estimates. No paratyphoid fever data were available 
for Super Region 2 (Central Europe, Eastern Europe, Cen-
tral Asia), Super Region 3 (Southern Sub-Saharan Africa, 
Central Sub-Saharan Africa, West Sub-Saharan Africa, East 
Sub-Saharan Africa), and Super Region 7 (Caribbean, An-
dean Latin America, Central Latin America, Tropical Latin 
America, Oceania). Extrapolations were made from Super 
Region 1 (Australia/New Zealand, Southern Latin America, 
High Income North America, High Income Asia Pacific, 
Western Europe) to Super Region 2; Super Region 5 (South 
Asia) to Super Region 3; and Super Region 6 (East Asia and 
South East Asia) to Super Region 7.
Twenty-two (88%) of the 25 eligible typhoid fever inci-
dence studies contained age-specific typhoid fever data for 
children <5 years and persons ≥5 and older (Table 3). Age-
specific data were available for 6 (29%) of 21 regions rep-
resenting 5 of 7 Super Regions. All data came from low- 
and middle-income countries. The median proportion of 
typhoid fever episodes among children <5 years was 
57.7%, and among persons ≥5 years, 42.3%. For Super 
Regions 3 and 5, the median proportion of typhoid fever 
cases among each age strata was used to calculate regional 
estimates of annual number of cases and incidence rates for 
each age group (Table 4).
The median typhoid fever incidence rate for each Super 
Region applied to the 2010 population estimates generates 
a crude global estimate of 13474369 typhoid fever episodes 
each year (Table 4). After adjusting for the low sensitivity 
of the blood culture typhoid test we estimate typhoid fever 
incidence to be 26948739 episodes annually.
There is little data to describe typhoid or paratyphoid fever 
case-fatality rates. In the most recent study on the global 
typhoid fever burden, Crump et al. assumed a case-fatality 
rate of 1% for typhoid fever based on hospital-based data, 
expert opinion, and mortality rates documented by ad-
Figure 1 Selection strategy flow diagram used to identify studies 
on typhoid and paratyphoid fever.V
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Table 1 Input data for typhoid fever incidence rates and summarized median incidence rates by Super Region*
Super region typhoid Fever caSeS perSon-yearS (p-yearS) incidence (epiSodeS/100 000 p-yearS)
Super Region 1
Australia/New Zealand [35,36] 695 17 753 491 3.9
463 7 731 880 6.0
Latin America, Southern [11-13]
164 136 525 120.1
68 65 718 103.5
28 30 906 90.6
North America, High Income [37] 7503 5 250 827 005 0.1
Asia Pacific, High Income [38] 388 1 021 033 000 0.0
Europe, Western [39]
31 33 211 134 0.1
207 31 918 266 0.6
10 3 131 242 0.3
50 21 861 785 0.2
35 21 159 333 0.2
832 255 015 133 0.3
468 328 973 094 0.1
38 44 771 106 0.1
51 17 372 910 0.3
219 237 547 356 0.1
1 1 922 572 0.1
1 1 636 715 0.1
192 65 583 388 0.3
140 42 413 512 0.3
98 179 344 312 0.1
108 36 600 283 0.3
1666 243 565 650 0.7
4 1 242 390 0.3
0 70 524 0.0
36 18 857 776 0.2
Median typhoid fever incidence rate per 100 000 p-years (IQR) 0.3 (0.1, 0.4)
Super Region 2
Europe, Central [39]
0 7 718 750 0.0
0 41 386 940 0.0
5 40 219 115 0.0
5 38 157 055 0.0
17 43 108 829 0.0
4 21 596 069 0.0
22 8 056 366 0.3
Europe, Eastern [39]
6 5 368 443 0.1
1 6 846 789 0.0
2 10 119 513 0.0
Asia, Central – – –
Median typhoid fever incidence rate per 100 000 p-years (IQR) <0.1 (0, <0.1)
Super Region 3
Sub-Saharan Africa, Southern [14] 173 20 459 845.6
Sub-Saharan Africa, Central – – –
Sub-Saharan Africa, West – – –
Sub-Saharan Africa, East [40] 794 131 550 603.6
<5 y ³5 y All ages
Median typhoid fever incidence rate per 100 000 p-years (IQR) 2552.3† 366.6† 724.6 (603.6, 845.6)
Super Region 4
North Africa/Middle East [15-17]
60 124 590 48.2
28 221 333 12.7
547 933 333 58.7
Median typhoid fever incidence rate per 100 000 p-years (IQR) 48.2 (12.7, 58.7)
Super Region 5
Asia, South [18-27]
49 12 407 394.9
63 6454 976.1
58 27 670 209.6
129 31 727 406.6
78 19 161 407.1
122 56 946 214.2
189 41 845 451.7
32 4887 654.7
60 15 219 394.2
78 57 075 136.7
49 29 170 168.0
80 56 946 140.5
96 37 608 255.3
<5 y ³5 y All ages
Median typhoid fever incidence rate per 100 000 p-years (IQR) 2104.1† 187.0† 394.2 (209.6, 407.1)
Super Region 6
Asia, East [20,22,23,28]
23 104 474 22.0
5 17 124 29.2
15 97 928 15.3
15 98 376 15.2
Asia, South East [20,22,23,29-32]
56 28 329 197.7
56 13 538 413.6
208 25 670 810.3
58 32 164 180.3
16 66 165 24.2
131 160 261 81.7
18 844 55 21.3
132 160 257 82.4
59 262 699 22.5
Median typhoid fever incidence rate per 100 000 p-years (IQR) 29.2 (22.0, 180.3)
Super Region 7
Caribbean – – –
Latin America, Andean – – –
Latin America, Central – – –
Latin America, Tropical – – –
Oceania [33,34] 275 1 672 000 16.4
275 979 781 28.1
Median typhoid fever incidence rate per 100 000 p-years (IQR) 22.3 (16.4, 28.1)
IQR – interquartile range
*Super Regions as defined by the Global Burden of Disease Project (Super Region 1: Australasia, Southern Latin America, High Income North America, 
High Income Asia Pacific; Super Region 2: Western Europe, Eastern Europe, Central Europe, Central Asia; Super Region 3: Southern Sub-Saharan Af-
rica, Central Sub-Saharan Africa, West Sub-Saharan Africa, East Sub-Saharan Africa; Super Region 4: Northern Africa/Middle East; Super Region 5: South 
Asia; Super Region 6: East Asia, South East Asia; Super Region 7: Caribbean, Andean Latin America, Central Latin America, Tropical Latin America, 
Oceania) [7].
†Derived from the following data: estimated annual number of typhoid fever episodes, median proportion of cases <5 and ³5 y of age and age-spe-
cific population estimates.V
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Table 2 Input data for paratyphoid fever incidence rates and summarized median incidence and mortality rates by Super Region*
Super region paratyphoiS Fever 
caSeS perSon-yearS incidence (epiSodeS/ 
100 000 p-yearS)
Super region incidence  
(epiSodeS/100 000 p-yearS)
Super region mortality  
(deathS/100 000 p-yearS)
median (iqr) median (iqr)
Super Region 1 8.0 (0.3, 20.6) <0.1 (0, 0.1)
Australia/New Zealand [36] 471 77 318 800 0.6
Latin America, Southern [11,12] 21 136 525 15.4
17 65 718 25.9
North America, High Income – – –
Asia Pacific, High Income [38] 219 1 021 033 000 0.0
Europe, Western – – –
Super Region 2† 8.0 (0.3, 20.6) <0.1 (0, 0.1)
Europe, Central – – –
Europe, Eastern – – –
Asia, Central – – –
Super Region 3† 77.4 (42.0, 130.3) 0.4 (0.2, 0.7)
Sub-Saharan Africa, Southern – – –
Sub-Saharan Africa, Central – – –
Sub-Saharan Africa, West – – –
Sub-Saharan Africa, East – – –
Super Region 4 0.8 (N/A) <0.1 (N/A)
North Africa/Middle East [17] 7 933 333 0.8
Super Region 5 77.4 (42.0, 130.3) 0.4 (0.2, 0.7)
Asia, South [21,23,25-27]
38 19 161 198.3
11 15 219 72.3
24 57 075 42.0
7 29 170 24.0
47 56 946 82.5
49 37 608 130.3
Super Region 6 17.9 (8.8, 27.4) 0.1 (0, 0.1)
Asia, East [23,28] 5 104 475 4.8
27 98 376 27.4
Asia, South East [23,29,31,32]
3 1 353 830 0.2
48 25 670 187.0
22 160 257 13.7
23 262 699 8.8
Super Region 7† 17.9 (8.8, 27.4) 0.1 (0, 0.1)
Caribbean – – –
Latin America, Andean – – –
Latin America, Central – – –
Latin America, Tropical – – –
Oceania – – –
p-years – person-years, IQR – interquartile range, N/A – not applicable
*Super Regions as defined by the Global Burden of Disease Project (Super Region 1: Australasia, Southern Latin America, High Income North America, 
High Income Asia Pacific; Super Region 2: Western Europe, Eastern Europe, Central Europe, Central Asia; Super Region 3: Southern Sub-Saharan Af-
rica, Central Sub-Saharan Africa, West Sub-Saharan Africa, East Sub-Saharan Africa; Super Region 4: Northern Africa/Middle East; Super Region 5: South 
Asia; Super Region 6: East Asia, South East Asia; Super Region 7: Caribbean, Andean Latin America, Central Latin America, Tropical Latin America, 
Oceania) [7].
†Extrapolation used to derive Super Region incidence estimate.
Table 3 An overview of studies with age-specific typhoid fever incidence rates by Super Regions
Super region*
<5 y 5 y
typhoid Fever 
caSeS
perSon 
-yearS
incidence 
(caSeS/100 000 
p-yearS)
proportion  
oF overall (%)
typhoid Fever 
caSeS perSon-yearS
incidence 
(caSeS/100 000 
p-yearS)
proportion oF 
overall (%)
Latin America, Southern [11-13] – – – – 68 65 718 103.5 N/A
– – – – 28 30 906 91.0 N/A
Sub-Saharan Africa, East [40] 240 23 167 1039.9 30.3 553 108 383 510.3 69.7
North Africa / Middle East [15-17] 9 157 631 5.8 7.6 545 775 114 70.4 92.4
Asia, South [18-27]
26 1393 1870.0 89.9 23 11 014 210.0 10.1
28 1027 2726.4 80.9 35 5427 644.9 19.1
11 4061 270.9 56.4 111 52 885 209.8 43.6
58 10 118 573.2 58.1 131 31 727 412.9 41.9
13 15 545 83.6 24.0 36 13 625 264.2 76.0
27 2089 1292.0 86.6 69 34 543 199.7 13.4
Asia, East [20,22,23,28] 0 489 0.0 0.0 23 103 985 22.1 100.0
– – – – 15 97 928 15.3 N/A
Asia, South East [20,22,23,29-32]
26 1989 1307.0 62.9 182 23 658 769.3 37.1
14 12 924 108.3 57.7 117 147 337 79.4 42.3
– – – – 18 84 455 21.3 N/A
Median proportion of cases split by 
<5 y and 5 y of age and older for low 
and middle income countries
57.7 42.3†
p-years – person-years, IQR – interquartile range, N/A – not applicable, y – years
*Super Regions as defined by the Global Burden of Disease Project (Super Region 1: Australasia, Southern Latin America, High Income North America, 
High Income Asia Pacific; Super Region 2: Western Europe, Eastern Europe, Central Europe, Central Asia; Super Region 3: Southern Sub-Saharan Af-
rica, Central Sub-Saharan Africa, West Sub-Saharan Africa, East Sub-Saharan Africa; Super Region 4: Northern Africa/Middle East; Super Region 5: South 
Asia; Super Region 6: East Asia, South East Asia; Super Region 7: Caribbean, Andean Latin America, Central Latin America, Tropical Latin America, 
Oceania) [7].
†Derived from the median proportion of overall cases attributable to children under 5 y of age.V
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Table 4 Annual number of typhoid fever episodes, 2010 by Super Region*
Super region 2010
Super Region 1 All ages
Population [41] 1 019 736 630
Median typhoid fever incidence rate per 100 000 p-years (IQR) 0.3 (0.1, 0.4)
Annual number of typhoid fever episodes (IQR) 3059 (1019, 4078.)
Super Region 2 All ages
Population [41] 406 303 917
Median typhoid fever incidence rate per 100 000 p-years (IQR) <0.1 (0, <0.1)
Annual number of typhoid fever episodes (IQR) 406 (0, 406)
Super Region 3 <5 y ³5years All ages
Population [41] 140 250 136 715 910 880 856 161 016
Median typhoid fever incidence rate per 100 000 p-years (IQR) 2552.3 366.6 724.6 (603.6, 845.6)
Annual number of typhoid fever episodes (IQR) 3 579 559† 2 624 183† 6 203 742 (5 167 787, 7 239 697)
Super Region 4 All ages
Population [41] 4 454 87 756
Median typhoid fever incidence rate / 100 000 p-years (IQR) 48.2 (12.7, 58.7)
Annual number of typhoid fever episodes (IQR) 214 725 (56 576, 261 501)
Super Region 5 <5 y ³5 y All ages
Population [41] 174 016 500 1 435 769 400 1 609 785 900
Median typhoid fever incidence rate per 100 000 p-years (IQR) 2104.1 187.0 394.2 (209.6, 407.1)
Annual number of typhoid fever episodes (IQR) 3 661 512† 2 684 263† 6 345 776 (3 374 111, 6 553 438)
Super Region 6 All ages
Population [41] 2 016 815 598
Median typhoid fever incidence rate per 100 000 p-years (IQR) 29.2 (22.0, 180.3)
Annual number of typhoid fever episodes (IQR) 588 910 (443 699, 3 636 318)
Super Region 7 All ages
Population [41] 528 026 317
Median typhoid fever incidence rate per 100 000 p-years (IQR) 22.3 (16.4, 28.1)
Annual number of typhoid fever episodes (IQR) 117 749 (865 96, 148 375)
Global Total: annual number of typhoid fever episodes 
(crude (IQR) / adjusted (IQR) ‡)
13 474 369 (9 129 791, 17 843 816) / 26 948 738 (18 259 583, 35 687 632)
p-years – person-years, IQR – interquartile range
*Super Regions as defined by the Global Burden of Disease Project (Super Region 1: Australasia, Southern Latin America, High Income North America, High In-
come Asia Pacific; Super Region 2: Western Europe, Eastern Europe, Central Europe, Central Asia; Super Region 3: Southern Sub-Saharan Africa, Central Sub-
Saharan Africa, West Sub-Saharan Africa, East Sub-Saharan Africa; Super Region 4: Northern Africa/Middle East; Super Region 5: South Asia; Super Region 6: East 
Asia, South East Asia; Super Region 7: Caribbean, Andean Latin America, Central Latin America, Tropical Latin America, Oceania) [7]
†Derived from median proportion of cases <5 and ³5 y of age (Table 5).
‡Adjusted to account for low sensitivity of blood culture typhoid test.
vanced national surveillance systems [1]. Given we found 
no new data to suggest an improvement in typhoid fever 
case fatality rates, we also used this figure to estimate the 
total number of annual deaths and to derive mortality es-
timates, which are presented in Table 5. Past studies on 
the global paratyphoid fever burden have not reported 
mortality estimates. Our study assumed a case-fatality rate 
of 0.5% given that paratyphoid fever is generally less severe 
than typhoid fever [42]. Mortality estimates for paraty-
phoid fever are presented in Table 2.
DISCUSSION
Our results suggest that in 2010, there were an estimated 
13.5 million typhoid fever episodes globally. This estimate 
is comparable to the 2000 crude estimate of 10.8 million 
episodes published by Crump et al [1]. We sought to up-
date the previous estimate and in doing so, found a num-
ber of more recently published studies with higher inci-
dence rates than those reported in older studies that 
influenced our final estimate. We used slightly different in-
clusion and exclusion criteria and applied slightly different 
methods for estimating incidence globally from the previ-
ous systematic review, which all contributed to the ob-
served differences. However, given that the world’s popu-
lation has grown by 10% in the last 10 years, our revised 
estimate, compared to the previously published 2000 esti-
mate, is well within a plausible margin of error.
Quantity of source data remains a major limitation for es-
timating the global burden of typhoid and paratyphoid fe-
ver. While additional data on paratyphoid fever is needed 
across all regions, typhoid fever estimates are limited by the 
scarcity of reliable incidence data from many of the devel-
oping regions in particular. Lacking surveillance systems 
or eligible population-based studies, typhoid fever inci-
dence data were unavailable for 7 (33%) regions including: 
Central Asia, Central Sub-Saharan Africa, West Sub-Saha-
ran Africa, Caribbean, Andean Latin America, Central Lat-
in America, and Tropical Latin America. Furthermore, in-
cidence estimates for several regions were based on few 
studies. Of note, we identified only 5 eligible studies con-
ducted in Africa. As a result, our estimate for Super Region 
3 – representing all of sub-Saharan Africa – was based on 
only two studies conducted in South Africa and Kenya 
[14,40]. Similarly, North Africa/Middle East estimates re-
lied on only 3 studies that were carried out in Egypt [15-
17]. Outside of Africa, there is also limited data available 
for Super Region 7. Only 2 studies from Fiji and Tonga 
were used to estimate the burden of disease for this region 
and both reported the results of pilot surveillance systems, 
thus there exists considerable uncertainty related to this 
approximation [33,34]. Additional population-based sur-
veillance studies must be carried out in Africa and other 
developing regions to develop a more accurate understand-
ing of the global typhoid fever burden.V
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We restricted our analysis to studies and surveillance sys-
tems that used blood culture as the criteria for diagnosis. 
Although typhoid and paratyphoid fever are most com-
monly diagnosed using this method, it is only 50% sensi-
tive. Factors that influence test sensitivity include antimi-
crobial use, the volume of blood collected, and the timing 
of blood collection [8,10,43]. These important limitations 
introduce a bias toward underestimation. In contrast, the 
inclusion of vaccine studies as a source for incidence data 
promotes a bias toward overestimation as sites are gener-
ally selected for having high incidence rates due to sample 
size considerations.
Typhoid and paratyphoid fever are major public health 
problems, especially in the developing world. Our study 
reports a revised estimate of the global burden of these dis-
eases based on new data available from recent population-
based studies and broader coverage of surveillance systems. 
In total, we identified 49 sources of new data that have be-
come available since the 2000 estimate published by 
Crump et al. in 2004 [1]: 15 population-based studies, 30 
national-surveillance systems, and 4 partially representa-
tive surveillance systems. Collectively, these sources pro-
vide estimates of overall typhoid fever incidence rates from 
14 (67%) of the 21 regions across 5 Super Regions.
Although our understanding of the global burden of these 
diseases has improved with more recent data, both en-
teric fevers remain poorly quantified. Critical gaps in our 
understanding persist, as the burden remains largely un-
known in many of the regions. Appreciable gains would 
be made by: a) developing improved diagnostic methods; 
b) implementing surveillance systems; and c) carrying out 
additional population-based research, particularly in sub-
Saharan Africa and other developing countries. Recent 
studies have shown that paratyphoid fever accounts for 
an increasing proportion of enteric fever in several regions 
[19,23,44-47]. If this trend continues, important chal-
lenges can be anticipated in the absence of an effective 
vaccine for this disease. In addition, multi-drug resistant 
S. typhi and S. paratyphi organisms may continue to in-
crease in prevalence and could certainly hamper efforts 
to reduce related morbidities. An accurate epidemiologi-
cal profile of the global burden of typhoid and paraty-
phoid fever is important to developing effective disease 
prevention and control strategies. 
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Table 5 Summarized median typhoid fever mortality rates by 
Super Region*
Super region region
mortality (deathS/ 
100 000 p-yearS) [1]
median (iqr)
Super Region 1
Australia/New Zealand [35,36]
<0.1 (0, <0.1)
Latin America, Southern [11-13]
North America, High Income [37]
Asia Pacific, High Income [38]
Europe, Western [39]
Super Region 2
Europe, Central [39]
<0.1 (0, <0.1) Europe, Eastern [39]
Asia, Central
Super Region 3
Sub-Saharan Africa, Southern [14]
7.2 (6.0, 8.5) Sub-Saharan Africa, Central
Sub-Saharan Africa, West
Sub-Saharan Africa, East [40]
Super Region 4 North Africa/Middle East [15-17] 0.5 (0.1, 0.6)
Super Region 5 Asia, South [18-27] 3.9 (2.1, 4.1)
Super Region 6 Asia, East[20,22,23,28] 0.3 (0.2, 1.8) Asia, South East [20,22,23,29-32]
Super Region 7
Caribbean
0.2 (0.2, 0.3)
Latin America, Andean
Latin America, Central
Latin America, Tropical
Oceania [33,34]
p-years – person-years, IQR – interquartile range
*Super Regions as defined by the Global Burden of Disease Project (Super 
Region 1: Australasia, Southern Latin America, High Income North Amer-
ica, High Income Asia Pacific; Super Region 2: Western Europe, Eastern 
Europe, Central Europe, Central Asia; Super Region 3: Southern Sub-Saha-
ran Africa, Central Sub-Saharan Africa, West Sub-Saharan Africa, East Sub-
Saharan Africa; Super Region 4: Northern Africa/Middle East; Super Region 
5: South Asia; Super Region 6: East Asia, South East Asia; Super Region 7: 
Caribbean, Andean Latin America, Central Latin America, Tropical Latin 
America, Oceania) [7].V
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